PL376721A1 - Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym - Google Patents

Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym

Info

Publication number
PL376721A1
PL376721A1 PL376721A PL37672103A PL376721A1 PL 376721 A1 PL376721 A1 PL 376721A1 PL 376721 A PL376721 A PL 376721A PL 37672103 A PL37672103 A PL 37672103A PL 376721 A1 PL376721 A1 PL 376721A1
Authority
PL
Poland
Prior art keywords
benzisothiazole
indol
piperazinyl
dihydro
chloro
Prior art date
Application number
PL376721A
Other languages
English (en)
Inventor
Timothy Norris
Roberto Colon-Cruz
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL376721A1 publication Critical patent/PL376721A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL376721A 2002-10-24 2003-10-13 Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym PL376721A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42084302P 2002-10-24 2002-10-24

Publications (1)

Publication Number Publication Date
PL376721A1 true PL376721A1 (pl) 2006-01-09

Family

ID=32176638

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376721A PL376721A1 (pl) 2002-10-24 2003-10-13 Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym

Country Status (24)

Country Link
US (1) US7019009B2 (pl)
EP (1) EP1556378B1 (pl)
JP (1) JP2006505578A (pl)
KR (1) KR100755625B1 (pl)
CN (1) CN100340557C (pl)
AR (1) AR041695A1 (pl)
AT (1) ATE383357T1 (pl)
AU (1) AU2003269331B2 (pl)
BR (1) BR0315516A (pl)
CA (1) CA2500485C (pl)
CO (1) CO5550441A2 (pl)
CY (1) CY1107300T1 (pl)
DE (1) DE60318602T2 (pl)
DK (1) DK1556378T3 (pl)
ES (1) ES2297200T3 (pl)
MX (1) MXPA05002734A (pl)
NO (1) NO20052475L (pl)
NZ (1) NZ566615A (pl)
PL (1) PL376721A1 (pl)
PT (1) PT1556378E (pl)
RU (1) RU2005112254A (pl)
TW (1) TW200418850A (pl)
WO (1) WO2004037819A1 (pl)
ZA (1) ZA200502109B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551346A1 (en) * 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
ATE254600T1 (de) * 1996-02-13 2003-12-15 Pfizer Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
CA2340701C (en) * 1998-08-20 2009-05-26 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivatives as growth hormone releasers

Also Published As

Publication number Publication date
TW200418850A (en) 2004-10-01
WO2004037819A1 (en) 2004-05-06
DK1556378T3 (da) 2008-03-17
EP1556378A1 (en) 2005-07-27
CN1705663A (zh) 2005-12-07
ATE383357T1 (de) 2008-01-15
AR041695A1 (es) 2005-05-26
CN100340557C (zh) 2007-10-03
DE60318602T2 (de) 2009-01-15
NO20052475D0 (no) 2005-05-23
CA2500485A1 (en) 2004-05-06
DE60318602D1 (de) 2008-02-21
NO20052475L (no) 2005-07-25
AU2003269331A1 (en) 2004-05-13
RU2005112254A (ru) 2006-01-20
CY1107300T1 (el) 2012-11-21
ZA200502109B (en) 2006-05-31
HK1081185A1 (en) 2006-05-12
AU2003269331B2 (en) 2010-02-18
JP2006505578A (ja) 2006-02-16
US7019009B2 (en) 2006-03-28
CA2500485C (en) 2010-03-23
US20040138232A1 (en) 2004-07-15
NZ566615A (en) 2009-08-28
KR20050065618A (ko) 2005-06-29
MXPA05002734A (es) 2005-05-23
PT1556378E (pt) 2008-02-21
CO5550441A2 (es) 2005-08-31
KR100755625B1 (ko) 2007-09-04
BR0315516A (pt) 2005-08-23
EP1556378B1 (en) 2008-01-09
ES2297200T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
CA2252895A1 (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
NO933093L (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on hydroklorid
CA2252898A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
AP2005003250A0 (en) Heterocyclic substituted piperazines for the treatment of schizophrenia.
IL166334A0 (en) Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
SI1572708T1 (sl) Novi heterociklicni fluoroglikozidni derivati, zdravila, ki vsebujejo te spojine, in njihova uporaba
NO20030394L (no) N-[5-[[[5-alkyl-2-oksazolyl]metyl]tio]-2-tiazolyl]karboksamid-inhibitorer for cyklin-avhengige kinaser
PL372969A1 (pl) Pochodne tiazolu i oksazolu modulujące aktywność PPAR
FI956279L (fi) Menetelmiä ja välituotteita 5-/2-(4-(bentsoisotiatsol-3-yyli)piperatsin-1-yyli)etyyli/-6-kloori-1,3-dihydroindol-2-onin valmistamiseksi
NO20006012D0 (no) 2-(3,5-Bis-trifluormetyl-fenyl)-N-metyl-N-(6-morfolin-4-yl-4- o-tolyl-pyridin-3-yl)-isobutyramid
ATE395333T1 (de) 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten
PL376721A1 (pl) Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym
AU2003260882A1 (en) Heterocyclic substituted piperazines for the treatment of schizophrenia
DE59906902D1 (de) Herbizide 3-(benzo(ox/thi)azol-7-yl)-1h-pyrimidin-2,4-dione
ATE254600T1 (de) Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
IL158929A0 (en) Oxazol/thiazol derivatives as activators of the hppar-alpha receptor
SI1556378T1 (sl) Acilni derivati 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperaznil)etil)-6-kloro-1,3-dihidro -2H-indol-2-ona z nevrolepticno aktivnostjo
CA2236940A1 (en) Processes and intermediates for preparing 3-(1-piperazinyl)-1,2-benzisothiazole
GB0220962D0 (en) Heterocyclic derivatives
HU0600868D0 (en) 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
MY109504A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2- one hydrochloride
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
HK1073465A (en) 5-substituted 1, 1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors
IS6696A (is) N-[5-[[[5-alkýl-2-oxazólýl]metýl]þíó]-2-þíazólýl]karboxamíð tálmar sýklínháðra kínasa

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)